Oncotarget

Research Papers:

MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma

Chen-Dan Zou _, Wei-Ming Zhao, Xiao-Na Wang, Qiang Li, Hui Huang, Wan-Peng Cheng, Jian-Feng Jin, He Zhang, Ming-Juan Wu, Sheng Tai, Chao-Xia Zou and Xu Gao

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:266-278. https://doi.org/10.18632/oncotarget.5689

Metrics: PDF 2287 views  |   HTML 3327 views  |   ?  


Abstract

Chen-Dan Zou1,*, Wei-Ming Zhao1,*, Xiao-Na Wang1, Qiang Li2, Hui Huang1, Wan-Peng Cheng1, Jian-Feng Jin1, He Zhang1, Ming-Juan Wu3, Sheng Tai2, Chao-Xia Zou1, Xu Gao1,4

1Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, China

2Department of General Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China

3Academy of Traditional Chinese Medicines, Harbin, China

4Heilongjiang Academy of Medical Science, Harbin, China

*These authors have contributed equally to this work

Correspondence to:

Chao-Xia Zou, e-mail: [email protected]

Xu Gao, e-mail: [email protected]

Keywords: hepatocellular carcinoma, microRNA, microRNA-107, CPEB3, EGFR

Received: March 30, 2015     Accepted: October 06, 2015     Published: October 17, 2015

ABSTRACT

MicroRNAs (miRNAs) are dysregulated in many types of malignancies, including human hepatocellular carcinoma (HCC). MiR-107 has been implicated in several types of cancer regulation; however, relatively little is known about miR-107 in human HCC. In the present study, we showed that the overexpression of miR-107 accelerates the tumor progression of HCC in vitro and in vivo through its new target gene, CPEB3. Furthermore, our results demonstrated that CPEB3 is a newly discovered tumor suppressor that acts via the EGFR pathway. Therefore, our study demonstrates that the newly discovered miR-107/CPEB3/EGFR axis plays an important role in HCC progression and might represent a new potential therapeutic target for HCC treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5689